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Abstract
INTRODUCTION: Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation techniques for the treatment 
of paroxysmal atrial fibrillation (PAF), with significantly improved efficacy compared to antiarrhythmic drugs as shown 
in CABANA trial. However, the question arises in which PAF patients whether the procedure can be limited to PVs only 
showing potentials (segmental), or it is really necessary to isolate all PV (circumferential). Even though success rates 
for circumferential PV ablation (CPVA) have been reported to be higher (up to 90%), than segmental PV ablation, most 
CPVA procedures previously reported included left atrial linear ablation, additional ablation lesions or lines connecting 
the mitral valve to the posterior PVs or along the roof of the left atrium which made bias to these studies. 
AIM: Thus, we initiated this randomized controlled study to evaluate the efficacy of CPVA versus SPVI in subjects 
undergoing ablation of PAF.
METHODS: Our study included 31 consecutive patients who underwent their first radiofrequency ablation for PAF 
between March 2015 and March 2017. Patients were randomized for circumferential or segmental ablation on the 
day of the procedure. We had two groups, circumferential (17 patients) and segmental group (14 patients).
RESULTS: There was no difference between two groups on our primary endpoint, the recurrence, which was 2 
out of 14 patients (14.3%) in the segmental ablation group, compared to 3 out of 17 patients (17.6%) who were 
circumferential ablated. This difference is statistically insignificant (p = 1). For other endpoints, there was also no 
statistically significant difference between circumferential and segmental regarding fluoroscopy time, 53.47 ± 8.7 min 
versus 54.93 ± 15.02 min, p = 0.738, procedure time, 184.18 ±19.28 min versus 191.43 ± 20 min p = 0.315, and even 
for radio frequency time which was lower in segmental group but did not differ statistically, 35.71 ± 5.73 min versus 
34.79 ± 5.29, min p = 0.649.
CONCLUSION: The previous studies showed the superiority of circumferential PVI on segmental strategy regarding 
effectiveness, but in those studies, linear ablations were added to circumferential strategy and done in cases of 
persistent and PAF. In our randomized study, we compared between two methods in cases of PAF, which showed 
that segmental ablation is not inferior to circumferential ablation of PVI.
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Introduction
Catheter ablation of atrial fibrillation (AF) has 
its roots in the surgical Maze procedure to cure AF 
developed by Cox [1]. The Maze procedure consists of 
a series of incisions in the right and left atria designed 
to develop anatomic barriers to conduction that would 
prevent maintenance of AF. This approach was 
patterned on the substrate-based mechanism of AF 
– the multiple wavelet theory of Moe [2]. According to 
this theory, large portions of the atria are involved in 
the development of multiple reentrant circuits that exist 
simultaneously to maintain AF. Therefore, the surgical 
procedure erects “road blocks” designed to prevent the 
perpetuation of these reentrant circuits.
The Maze surgery is reasonably effective 
but has not been accepted as a routine clinical 
technique [3]. An important part of the Maze technique 
is the isolation of the pulmonary vein (PV). In fact, in 
retrospect, this may have been the key to the success 
of the procedure [4]. More recent observations since 
the late 1990s from Haïssaguerre et al. [5] have 
demonstrated that the initiators of AF typically originate 
in the PVs, and isolation of these veins often prevents 
AF. This observation supports the ectopic focus theory 
of AF proposed by Scherf et al. decades ago [6]. It is 
now known that rapidly firing foci can occur outside 
of the PVs such as the superior vena cava, coronary 
sinus, and less commonly other areas in the right and 
left atria.
The initial catheter ablation approach attempted 
to mimic the Cox surgical Maze procedure and consisted 
of multiple linear ablation lines introduced in the right 
and left atria. Success was not high, and serious 
complications were too frequent. The realization that in 
humans, at least in patients with paroxysmal AF (PAF), 
the PVs are the prime initiating focus of AF has led to a 
sea change in the ablation approach to curing AF.
Currently, the primary objective is to isolate 
the PVs from the left atrium (LA). In patients with 
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long-standing persistent AF, left atrial tissue outside of 
the PVs may play a prominent role in the maintenance 
of AF, and this requires additional ablation lesions. In 
essence, the respective role of initiator and substrate 
to maintain AF is clearly not distinct in many patients, 
and various patient subgroups may require combined 
ablation approaches to achieve a successful outcome.
Methodology
This is a prospective randomized controlled 
clinical trial that was conducted between May 2015 and 
May 2017 and under follow-up for 1 year, in the Critical 
Care Medicine Department – Cairo University. Our 
study design involved 17 patients in Group I, age (53.76 
± 5.71), sex (11 males, and 6 females), left ventricular 
ejection fraction (LVEF) (57.59 ± 5.79), left atrial 
diameter (LAD) (4.05 ± 0.22), hypertension (6 patients, 
35.3%), and diabetes mellitus (DM) (5 patients, 29.4%). 
Our study design involved 14 patients in Group II, age 
(54.14 ± 6.14), sex (7 males, and 7 females), LVEF 
(59.07 ± 5.30), LAD (3.93 ± 0.21), HTN (5 patients, 
35.7%), and DM (2 patients, 14.3%).
Our primary endpoints were to evaluate 
the recurrence rate, procedure data, and major 
complications related to circumferential versus 
segmental PVs isolation after the first AF ablation 
procedure. Secondary endpoints included identifying 
(1) other possible predictors of AF recurrence after 
ablation, and (2) determinants of predictors of increasing 
fluoroscopy time, mapping time, and procedure time.
Inclusion criteria
The following criteria were included in the study:
• Patients known to have PAF refractory to at 
least one antiarrhythmic drug.
• Patients who are maintained on sinus rhythm 
by medications.
• Patients >18 years old.
Exclusion criteria
The following criteria were excluded from the 
study:
• Patients with medical conditions that would 
limit participation for the entire study duration 
(diseases with life expectancy <1y)
• Patients having the previous stroke
• Patients with persistent/permanent AF
• Congestive heart failure
• LA diameter >5.5 cm.
• Uncontrolled thyrotoxicosis or ischemic heart 
disease.
For all patients enrolled in the study, 
demographic and clinical data were recorded, including 
AF symptomatic details, electrocardiograms (ECGs), 
Echo, and computed tomography (CT) scan (if possible). 
The consent from all patients was signed before the 
procedure and after explaining all procedure steps 
and potential complications according to European 
guidelines 2016 [7], American guidelines 2017 [8].
Pre-procedural preparations
There were two pre-procedural protocols for 
anticoagulation according to operator preference; 
Warfarin was discontinued before the procedure for at 
least 5–7 days, with bridging with low-molecular-weight 
heparin (LMWH) for 3 days before ablation, allowing 
international normalized ratio (INR) to drop to normal 
(or near normal <1.2) level on the day of ablation. In this 
protocol, LMWH was discontinued on the night before 
the procedure and restarted 6 h after procedure along 
with Warfarin, provided adequate hemostasis. Once 
INR had risen to 2–3, LMWH was discontinued.
The other protocol involves continuing 
Warfarin or NOAC without interruption and performing 
the procedure on therapeutic INR of 2–3.
The absence of LA thrombus was confirmed by 
a transesophageal echocardiogram.
According to our study protocol, antiarrhythmic 
medications (Amiodarone) were continued for at least 
3 months after the procedure (the blanking period).
Procedure
On the day of the procedure, all patients signed 
informed written consent.
Patient monitoring during the procedure
Surface ECG and bipolar endocardial 
electrograms were stored continuously using multichannel 
polygraph (Lab System PRO®, Bard Electrophysiology or 
WorkMate Claris™, St. Jude) for further analysis. Bipolar 
recordings were filtered from 30 to 500 Hz. Arterial blood 
pressure (BP) and SpO2 were continuously monitored. 
All patients had the procedure done under conscious 
sedation (Midazolam, induction by 0.3 mg/kg bolus dose 
over 20–30 s, and maintenance by 0.05 mg/kg boluses 
if needed), local anesthesia (lidocaine HCL 2%, 400 mg 
intradermal), and analgesics (Paracetamol, 1000 mg IVI 
over 3 h, Morphine 2–4 mg repeated 1–2 h if needed with 
maximum cumulative dose 10 mg).
Trans-septal puncture
Trans-septal puncture was guided by 
fluoroscopy and multipolar catheter placed in coronary 
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sinus. In addition, aortic root was marked by either 
his catheter or pigtail catheter placed retrogradely at 
the aortic root. One or Two 8F long sheaths (Mullin or 
preface) were then placed in LA through the puncture 
(Figure 1).
Few cases (3 patients) trans-septal were done 
under the guidance of Intra Cardiac Echo, according to 
operator choice.
In 11 patients, transesophageal echo was used 
for trans-septal puncture.
Description of the procedure
Following trans-septal puncture, weight-
adjusted unfractionated heparin (UFH) was administered 
to achieve an ACT of 300-350. ACT was then repeated 
every 15–30 min, and UFH was given accordingly to 
maintain the measurements within the target.
Mapping
We defined mapping time as the time from 
inserting circular map catheter till definition of all PVs 
using the 3D navigation system in most of cases 
(25 patients, 80.7%), CARTO3 (Biosense Webster, 
Johnson and Johnson), or NavX, (EnSite Velocity, St. 
Jude) was used for LA shell construction.
In other patients, (6 patients 19.3%), PVs were 
mapped conventionally by fluoroscopy.
Marking of PVs and ostia delineation were 
carefully done before the procedure to have an idea 
about the anatomy of the PVs and detecting the antrum; 
we applied three methods for that:
1. Merging of CT angiography of LA with electro-
anatomical map (12 patients, 38%)
2. Selective pulmonary angiography or LA 
angiography (5 patients, 16%). We used 
multipurpose catheter and 10 cc of contrast 
without dilution and manually inject it in each 
PV (in selective pulmonary angiography) or 
in LA and record it on fluoroscopy. PV is a 
funnel shaped, with a tube that fans out into 
a proximal “cup” that blends into the posterior 
atrial wall, which we refer to as the antrum [9], 
(Figure 1)
3. When the previous two methods were not 
available or not conclusive (14 patients, 
45%), we were depending on the impedance 
difference between the vein, which is high 
(>190 ± 45 ohm) and the LA (< 120 ± 30 ohm). 
We mark the best place by a circular map and 
record it on fluoroscopy.
In our study, we found 6 patients (19.4%) with 
left common ostium, and 3 patients (9.7%) with the 
absence of right inferior PV.
Radio frequency (RF) ablation
A fully expanded 10-pole (electrode width 
1 mm, inter-electrode distance 8 mm) or 20-pole 
(electrode width 1 mm, inter-electrode distance is 
2-5-2 mm) circular mapping catheter (Lasso 2515, 
Biosense Webster, Diamond Bar, CA, USA) was then 
placed as proximal as possible in PV ostium, and the 
vein was isolated by either circumferential or segmental 
by RF ablation extra ostial. Patients were randomized 
for the ablation approach according to admission ID.
Circumferential PV isolation (PVI)
Ipsilateral PVs were encircled as a unit by a 
common lesion, except for 2 patients, in whom right inferior 
PV was absent. Continuous lesions were always completed 
(Figure 2), and if PV disconnection was not achieved after 
completion of the PV encircling, conduction gaps in the 
circumferential lesion were identified, and ablation was 
continued until full PV disconnection was achieved.
There was no any addition of ablation lines in 
all patients.
Segmental PVI
In our study, we have 14 cases with segmental 
ablation. Eight patients were done guided by electro-
anatomical map, where the ablation targeting myocardial 
LA–PV breakthroughs (Figures 3 and 4).
Figure 1: Angiography for LSPV, showed a funnel-shaped PV, a tube 
(PV) that fans out into a proximal “cup” (antrum), LSPV: Left superior 
pulmonary vein, PV: Pulmonary vein
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Figure 2: Posterior and modified clipped RL view of FAM of the left 
atrium showed circumferential ablation of pulmonary vein isolation. 
FAM: Fast anatomical map. RL: Right lateral
Other six patients were done conventionally 
and ablation was guided by the circular catheter. The 
RF energy was applied as proximal as possible but 
carefully extra ostial – detected previously during 
mapping – by adjusting it behind circular catheter on 
fluoroscopy (Figure 5).
Figure 3: 20 poles lasso is placed at RSPV. (a) Posterior view of 
activation map of left atrium showing segmental ablation points at 
RPVs. (b) RSPVs before ablation. (c) RSPVS after pulmonary vein 
isolations. RSPV: Right superior pulmonary veins. RPVs: Right 
pulmonary veins
a
b
c
Ablation was finished at the moment of 
stable complete PV disconnection. Thus, RF energy 
applications did not inevitably cover the entire 
circumference of the PV ostia.
Figure 4: 20 poles lasso is placed at LSPV. (a) LL view activation 
map of left atrium showing segmental ablation points at the left ridge. 
(b) LSPV before ablation. (c): LSPV after ablation. LL: Left lateral, 
LSPVs: Left superior pulmonary veins
ca
b
In most patients, standard 3.5mm irrigated-tip 
ablation catheter was used; however, pressure-sensing 
3.5mm irrigated-tip catheter (Thermocool® SmartTouch® 
catheter, Biosense Webster) was sometimes used 
(9 patients, 29%).
Whenever the pressure-sensing catheter was 
used, all attempts were made to keep tip pressure 
between 10 and 30 g all through RF applications. 
The energy delivered for all catheters was 25W on 
the posterior wall and roof of LA and 30W elsewhere. 
Ablation catheter was continuously irrigated using 
Heparinized Saline at the background rate of 2 ml/min 
that increases to 17 ml/min during RF application. RF 
energy was applied with a Stockert (Biosense-Webster, 
Diamond Bar, CA, USA) generator.
In all cases, Full PV isolation was defined as 
complete elimination of all high-frequency PV potentials 
recorded by the ring catheter during SR or atrial pacing, 
demonstration of entrance block into the vein was 
a mandatory endpoint. After isolating all veins that 
demonstrated PVP’s, veins were re-checked at least 
20 min later for gaps.
According to operator discretion, adenosine 
was sometimes given to unmask dormant conduction 
into PV, when found. Adenosine was given after 20 min 
of PVI, at a dose that produced complete AV block or 3 s 
pause (Figure 6). We had 3 patients with spontaneous 
induction of AF at beginning and during the procedure 
(1 in circumferential group and 2 in segmental group) 
and remained at the end of PVI. There were electrically 
cardioverted, and all veins were re-checked in sinus 
rhythm.
At the end of the procedure, protamine was 
given, at operator discretion if last ACT >250 to reverse 
the effect of heparin. Catheters were removed and 
hemostasis was ensured by compression plus figure 
of eight closure of puncture site if needed. Procedure 
Figure  5:  LAO  fluoroscopic  view  showed  conventional  segmental 
ablation of LSPV. LAO: Left anterior view. LSPV: Left superior 
pulmonary vein
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time (from skin puncture to removal of sheaths) and 
fluoroscopy time were recorded.
Post-procedural management
Echo was done routinely for all patients after 
ablation and once patients arrive at the ward, ECG 
was continuously monitored. Twelve-lead ECG was 
recorded, along with all vital signs. According to the 
protocol, oral anticoagulation was resumed on the 
night of the procedure, provided adequate hemostasis, 
along with antiarrhythmic medication. If there were 
no complications, patients were discharged on the 
following day after ensuring stable hemodynamic and 
receiving post-ablation instructions and follow-up plans.
Follow-up, monitoring of recurrence
All patients were instructed to continue the 
same antiarrhythmic medication they used before 
ablation, for a minimum of 3 months (blanking period).
All patients had routine follow-up visits after 
1 month, 3 months, 1 year, and in each visit, detailed 
history and 12 leads ECG was done for confirmation of 
sinus rhythm (normal sinus rhythm) and for any attack 
of palpitations during this period. If the attack was too 
short to be recorded, a 24–48 h Holter was done.
At the end of blanking period, all patients, who 
did not experience any palpitations in the blanking 
period, had at least 24 h Holter and if it was free, 
antiarrhythmic medication would be stopped.
Regarding anticoagulation, the decision of 
stopping is depending mainly on CHA2DS2VASC.
At the end of 1 year after ablation, all patients 
without documented AF recurrence after the blanking 
period had a 12-lead ECG and at least 24 h Holter. In our 
study, AF recurrence was defined as documented AF/AT 
episode longer than 30 s with or without symptoms.
In each of the two follow-up visits, patients were 
also asked and examined for possible complications 
related to ablation such as thromboembolism, PV stenosis, 
phrenic nerve injury, and atrioesophageal fistula.
Statistical methods
Data were coded and entered using the statistical 
package SPSS version 25. Data were summarized using 
mean and standard deviation for quantitative variables and 
frequencies (number of cases) and relative frequencies 
(percentages) for categorical variables. Comparisons 
between groups were done using unpaired t-test when 
comparing two groups and analysis of variance (ANOVA) 
with multiple comparisons post hoc test when comparing 
more than 2 groups [10]. For comparing categorical 
data, Chi-square (χ2) test was performed. Exact test was 
used instead when the expected frequency is <5 [11]. 
Correlations between quantitative variables were done 
using the Pearson correlation coefficient [12]. p < 0.05 
was considered as statistically significant.
Results
Our study included 31 consecutive patients 
who underwent their first radiofrequency ablation for 
PAF between March 2015 and March 2017, and 1 year 
follow-up, in Critical Care Medicine Department – Cairo 
University. In all cases, PVI confirmed by the entrance 
block was a standard target. All patients were followed 
up for a minimum of 1 year. According to the study 
protocol, patients were randomized for circumferential 
or segmental ablation on the day of the procedure.
We had two groups, circumferential group 
(17 patients) and segmental group (14 patients).
Mapping of LA and PVs was done by 3D 
electroanatomical map, or conventionally by fluoroscopy.
Our primary endpoint was to study the effect 
of the two strategies of ablation circumferential versus 
segmental on the recurrence.
Group characteristics
Characteristics of study population and study 
groups are listed in Table 1.
Figure 6: Adenosine 12 mg injection after 20 min of left superior 
pulmonary vein isolation, showed no dominant conduction
Table 1: Characteristics of the study population and study 
groups
Variable All n=31 Group 1 
(circumferential) n=17 
(54.8%)
Group 2 (segmental) 
n=14 (45.2%)
p
Age (years) 53.9 ± 5.8 53.7 ± 5.7 54.1 ± 6.1 >0.05
Gender (M) 18 (58.1%) 11 (64.7%) 7 (50%) >0.05
Hypertension 11 (35.5%) 6 (35.2%) 5 (35.7%) >0.05
DM 7 (22.5%) 5 (29.4%) 2 (14.2%) >0.05
CAD 1 (3%) 1 (5%) 0 >0.05
RWMA 1 (3%) 1(5%) 0 > 0.05
Asthma 1 (3%) 0 1 (7%) > 0.05
COPD 1 (3%) 0 1 (7%) > 0.05
RHD 1 (3%) 1 (5%) 0 >0.05
LAD 3.9 ± 0.2 4 ± 0.2 3.9 ± 0.2 >0.05
Normal PV 22 (70%) 12 (70.6%) 10 (71.4%) >0.05
Abnormal PV 9 (29%) 5 (29%) 4 (28%) >0.05
Right PV anomaly 2 (11.8%) 1 (7.1%) >0.05
Lt common os 3 (17.6%) 3 (21.4)
LVEF 58.2 ± 5.5 57.5 ± 5.7 59 ± 5.2 > 0.05
COPD: Chronic obstructive pulmonary disease, CAD: Coronary artery disease, DM: Diabetes mellitus, 
LVEF: Left ventricular ejection fraction, LAD: Left atrial diameter, M: Male, RHD: Rheumatic heart disease.
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Analysis of primary endpoint
Our study showed that segmental ablation is 
not inferior to circumferential ablation as an effective 
method for ablation for PAF over the follow-up period 
of 1 year (Figure 7). Atrial fibrillation recurred in 2 
out of 14 patients (14.3%) in the segmental ablation 
group, compared to 3 out of 17 patients (17.6%) who 
were circumferentially ablated. This difference was 
statistically insignificant (p < 0.05).
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3 2
14 12
AF recurrence No AF recurrence
P > 0.05
Figure 7: Effect of  circumferential and segmental ablation on atrial 
fibrillation recurrence
Regarding mapping time (Figure 8), 
circumferential versus segmental was: 23.59 ± 6.19 min 
versus 24.14 ± 5.26 min p = 0.793.
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Figure 8: Mapping time in the conventional group compared to the 
segmental group
Radiofrequency ablation time was longer 
in the circumferential group, although there was no 
statistically significant difference.
0
5
10
15
20
25
30
35
40
45
circumferential segmental
R
F 
tim
e
P > 0.05
Figure 9: Radiofrequency ablation time in the conventional group 
compared to the segmental group
Circumferential versus segmental group was 
35.71 ± 5.73 min versus 34.79 ± 5.29 min p = 0.649 
(Figure 9).
Furthermore, there was no statistical difference 
between segmental and conventional group concerning 
procedure and fluoroscopy time, 184.18 ± 19.28 min 
versus 191.43 ± 20 min, p = 0.315 (Figure 10) and 
53.47 ± 8.7 min versus 54.93 ± 15.02 min, p = 0.738 
(Figure 11), respectively.
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Figure 10: Mapping time in the conventional group compared to the 
segmental group
Post-ablation complications
Comparison between early 
(pericardial tamponade) and late complications (post-
ablation atrial flutter or atrial tachycardia) in both groups, 
there was no difference.
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Figure 11: Fluoroscopy time in conventional group compared to 
segmental group
Pericardial tamponade
Cardiac tamponade was diagnosed by a 
reduction in the excursion of the cardiac silhouette 
on fluoroscopy with a simultaneous fall in systemic 
BP.
All cases were drained by pigtail catheter inside 
EP lab using epicardial puncture under the guidance of 
fluoroscopy. We used protamine IV injection depending 
on the dosage and the last time of heparin injection, for 
all patients after drainage.
After 24 h, pigtail catheter was removed 
after confirmation of drained pericardium, by 
echocardiography, and patients were discharged.
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Table 2: Pulmonary vein mapping techniques
Mapping technique 3D mapping circumferential 17 100.0%
3D mapping segmental 8 57.1%
lasso segmental 6 42.9%
Pericarditis
Tamponading patient in Group II (circumferential 
ablation) developed pericarditis that was controlled by 
steroid (prednisone 20 mg with gradual tapering within 
3 weeks).
Table 3: Insignificant difference between segmental and 
conventional ablation groups regarding procedure data
Procedure data Group
Group I (Circumferential 
ablation)
Group II 
( Segmental ablation)
p
Mean ± SD Mean ± SD
Time of mapping 23.59 ± 6.19 24.14 ± 5.26 >0.05
Radio frequency time 35.71 ± 5.73 34.79 ± 5.29 >0.05
Procedure time 184.18 ± 19.28 191.43 ± 20.10 >0.05
Fluoroscopy time 53.47 ± 8.70 54.93 ± 15.02 >0.05
PV stenosis
We did not have any case diagnosed clinically 
as PV stenosis (unexplained cough, and dyspnea).
Predictors of recurrence
Several clinical variables have been analyzed 
aiming at identifying possible predictors of AF recurrence 
after ablation (Tables 4 and 5). 
Table 4: Post-atrial fibrillation complication in Group I 
(Circumferential ablation) and Group II (segmental ablation)
Complications Group I (%) Group II (%) p
Total (17) Total (14)
Pericardial tamponade pericarditis 1 (5.8) 1 (7.1) >0.05
1 (5.8) 0 (0)
Post ablation A.Flu/AT 3 (17.6) 0 (0) >0.05
Total complications 4 (23) 1 (7) >0.05
A.flu: Atrial flutter, AT: Atrial tachycardia.
Of the clinical variables, the only recurrence in 
blanking period (Table 5) was seen prevalent in the AF 
recurrence group.
Table 5: Categorical variables for predicting atrial fibrillation 
recurrence
Categorical variables Count Recurrence after 1 year
Yes No p
Count (%) Count (%)
Sex Male (18) 2 (40) 16 (61.5) >0.05
Female (13) 3 (60) 10 (38.5)
HTN Yes (11) 2 (40) 9 (34.6 >0.05
No (20) 3 (60) 17 (65.4)
Diabetes mellitus Yes (7) 1 (20) 6 (23.1) >0.05
No (24) 4 (80) 20 (76.9)
IHD Yes (1) 0 (0) 1 (3.8) >0.05
No (30) 5 (100) 25 (96.2)
Asthma Yes (1) 0 (0) 1 (3.8) >0.05
No (30) 5 (100) 25 (96.2)
COPD Yes (1) 0 (0) 1 (3.8) >0.05
No (30) 5 (100) 25 (96.2)
RHD Yes (1) 0 (0) 1 (3.8) >0.05
No (30) 5 (100) 25 (96.2)
Anatomy of PV Normal (23) 4 (80) 18 (69.2) >0.05
Abnormal (9) 1 (20) 8 (30.8)
Recurrence in blanking period 
(1st 3 months)
Yes (2) 2 (100) 0 (0) 0.02
No (29) 3 (10.3) 26 (89.7)
PV: Potential vorticity, RHD: Rheumatic heart disease, COPD: Chronic obstructive pulmonary disease.
Analysis of correlation between LA 
anteroposterior diameter (LAD), and fluoroscopy time 
Figure 12, mapping time Figure 13, and radiofrequency 
time Figure 14, was no significant.
Figure 12: Relationship between left atrium diameter and fluoroscopy time
Figure 13: Relationship between left atrium diameter and mapping time
Figure 14: Relationship between left atrium diameter and radiofrequency 
time
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Correlation between abnormal anatomy of 
PVs in form of left common os (6 patients, 19.4%) 
and accessory of right PVs (3 patients, 9.7%), showed 
lesser radiofrequency time without affecting mapping, 
fluoroscopy, and procedure time.
Discussion
There is no doubt that AF is the disease of 
the present and the future, we have understood a 
lot about its pathogenesis and management, but we 
are still missing the complete cure, although in last 
few years, we have a technological revolution with 
many evolving hypotheses and new techniques for 
managing AF.
Long story of struggle starting by Cox et al. [13] 
with the first step of success in early 1990 by the 
introduction of MAZE-3 [13], [14] which motivated the 
scientific staff for adopting the same surgical concept 
for catheter ablation.
Second success and most important station in 
AF ablation history were done by Haïssaguerre et al. by 
the identification of PVs as the site of triggers for AF [15], 
then an ablation strategy of encircling the PVs guided 
by 3D electroanatomical mapping was subsequently 
developed by Pappone et al. [16].
However, there is controversy in the literature 
regarding the most effective approach (i.e. segmental 
vs. circumferential) to achieve durable PVI and ensure 
long-term success in preventing recurrence of AF. In 
fact, there is no definitive prospective randomized study 
published to date, with a large enough population of 
patients, over an acceptable duration of follow-up, and 
with adequate monitoring to ensure identification of AF 
recurrence, which convincingly proves one method as 
being superior to achieve durable PVI and long-term 
suppression of AF [17].
Effectiveness of segmental versus 
circumferential ablation of AF on recurrence
Ablation of the triggers at PVs was either 
performed segmentally, guided by a circular mapping 
catheter [18] positioned close to the PV ostium, the so 
called segmental PV ablation or by wider continuous 
circumferential ablation lesions created to surround 
the right or left PVs [19] the so-called wide area 
circumferential ablation (WACA).
In our study, we compared between WACA 
and extra -ostial or antral segmental ablation. One of 
the primary endpoints was the effectiveness of both 
strategies on recurrence after 12 months of follow.
Atrial fibrillation recurred in 2 out of 14 patients 
(14.3%) in the segmental ablation group, compared to 
3 out of 17 patients (17.6%) who were circumferential 
ablated, (p > 0.05). Accordingly, segmental is not inferior 
to circumferential PVs ablation.
Several studies have been published 
comparing segmental with circumferential PVI for the 
treatment of AF. In one such study by Karch et al. [20], 
100 patients with symptomatic AF were randomized to 
either circumferential (n = 50) or segmental (n = 50), 
and freedom from atrial tachyarrhythmias was assessed 
using a 7-day Holter monitor at 6 months follow-up. 
Twenty-one patients (42%) were free from any atrial 
tachyarrhythmias, including AF after circumferential 
and 33 patients (66%) after segmental (p = 0.02).
This study result is supported later with other 
studies, as in a study of 80 patients with PAF performed by 
Mansour et al. [21] 40 patients underwent segmental PVI, 
and 40 patients underwent circumferential PVI. At 11 ± 
2.5 months, 24 patients (60%) who underwent segmental 
and 30 patients (75%) underwent circumferential were free 
of symptomatic PAF. There was no statistically significant 
difference between the two approaches for PVI.
Worth mentioning, in this study, additional 
ablation lines were done at the mitral isthmus with the 
circumferential approach.
Fiala et al. [22] suggested that circumferential 
PVI would improve the outcome in patients with PAF 
Table 6: Numerical variables for predicting of atrial fibrillation 
recurrence
Numerical variables Recurrence 1 year p
Yes No
Mean ± SD Mean ± SD
Age 50.80 ± 3.90 54.54 ± 5.97 >0.05
LAD 4.12 ± 0.26 3.97 ± 0.21 >0.05
LAD: Left atrial diameter.
Figure 15: Post hoc analysis for relation of radio frequency (RF) time 
and abnormal anatomy of pulmonary veins showed left common 
ostium as an independent factor for decreasing of RF time
Table 7: Relationship between pulmonary veins abnormal 
anatomy and mapping, RF, procedure, and fluoroscopy time
Numerical 
variables
Anatomy of PV p
Normal Lt common os Rt PV anomaly
Mean ± SD Mean ± SD Mean ± SD
Time of mapping 22.73 ± 4.62 24.67 ± 7.47 30.33 ± 6.66 >0.05
RF time 36.91 ± 5.07 31.33 ± 2.94 31.33 ± 7.57 0.03
procedure time 189 ± 21.16 180.83 ± 15.13 189.33 ± 19.14 >0.05
Fluoro time 56.41 ± 11.08 52.5 ± 12.72 40.67 ± 7.02 >0.05
RF: Radiofrequency, PV: Potential vorticity.
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comparing to the segmental approach. Fifty-four 
patients underwent segmental (Group 1) and 
56 patients underwent circumferential (Group 2), in a 
randomized study with follow-up for 48 ± 8 months. 
After a single procedure, 30 patients (56%) in Group 1 
and 32 patients (57%) in Group 2 remained free of 
arrhythmia (p = 0.41). The authors concluded that there 
was no advantage in long-term arrhythmia free clinical 
outcomes after circumferential versus segmental RF 
ablation in PAF.
In contrast to our results, some other studies 
showed the superiority of circumferential versus 
segmental PVI approach in AF patients.
Oral et al. [23] studied 80 consecutive patients 
with symptomatic PAF, of whom 40 underwent PVI by 
segmental ablation and 40 underwent circumferential 
ablation. At 6 months, 67% of patients who underwent 
segmental and 88% of patients who underwent 
circumferential were free of symptomatic PAF (p = 0.02).
In this study, additional linear ablation was 
performed at the mitral isthmus connecting the mitral 
valve annulus to the left circumferential lesion and at the 
posterior LA connecting the left and right circumferential 
ablation lesions (box isolation) which could interpret this 
significant difference in favor of circumferential ablation 
in which decreasing LA critical mass by isolation of 
posterior wall of LA.
In Nilsson et al., study [24] that included 
100 patients with symptomatic AF, 54 patients were 
randomized for segmental ablation and 46 patients 
for the circumferential group. During a mean follow-up 
of 12 months without antiarrhythmic drugs, 57% of 
patients who underwent circumferential PV isolation 
were free of arrhythmia symptoms compared to 31% of 
patients who underwent segmental ablation (p < 0.05).
This difference in success rate between the 
two ablation strategies was mainly seen, however, 
in patients with known persistent AF (52% vs. 15%; 
p = 0.02), as opposed to patients with PAF (65% vs. 
46%; p = 0.26).
Procedure time, fluoroscopic time, 
mapping time, and RF ablation time
In our study, there was no statistically significant 
difference between circumferential versus segmental 
regarding fluoroscopy time, 53.47 ± 8.7 min versus 
54.93 ± 15.02 min, p > 0.05, procedure time, 184.18 ± 
19.28 min versus 191.43 ± 20 min, p > 0.05, and even 
for RF time which was lower in segmental group but did 
not differ statistically, 35.71 ± 5.73 min versus 34.79 ± 
5.29, min p > 0.05.
In large meta-analysis comparing between 
circumferential and segmental ablation, published 
in 2014 [25], data on total procedure duration and 
fluoroscopy time were reported in Calkins et al. [8], [22], 
[26], [27], [28], [29], [30], and [10], [21], [23], [24], [26], 
[27], [28], [31], [22], [30], [32] studies, respectively.
Overall, the total procedure duration was 
significantly longer in the circumferential group than 
that in the segmental PVI group, (mean difference, 
17.22 min 95% CI, 11.09–23.34), whereas the total 
fluoroscopy time was significantly reduced, mean 
difference, −9.25 min (95% CI, −10.50–−8.01). 
Radiofrequency application time was reported in Perez-
Lugones et al. [9], Mansour et al. [21], Oral et al. [23], 
Nilsson et al. [24], Liu et al. [26], Arentz et al. [27], Jin 
Hwang et al. [28], Sawhney et al. [31], Tan et al. [30], 
Yamane et al. [32] studies. The circumferential group 
had longer times mean difference, 11.87 min (95% CI, 
10.45–13.30 min).
To the best of our knowledge, there is no study 
that includes mapping time as a comparable item, which 
is defined in our study as the time from inserting circular 
map till definition of all PVs. Our statistics showed there 
was no difference between circumferential versus 
segmental ablation, 23.59 ± 6.19 min versus 24.14 ± 
5.26 min p >0.05.
LA size and PVs anomalies and effect on 
mapping, fluoroscopy, and ablation time
The LA diameter (anteroposterior size, 3.99 ± 
0.22 cm), had no relation or any effect on fluoroscopy, 
mapping, and RF ablation time, for three items, p > 0.05
It was not the same for PVs anatomy, as 
abnormal PV anatomy in the form of left common 
ostium (6 patients, 19.4%), or accessory right PVs 
(3 patients, 9.7%) affected significantly radiofrequency 
ablation (normal anatomy, left common ostium, and 
right accessory PVs, RF time was 36.91 ± 5.07, 31.33 
± 2.94, and 31.33 ± 7.57, respectively, p < 0.05) without 
affecting mapping (p > 0.05) or fluoroscopic time 
(p > 0.05).
Sub statistical analysis showed left common 
ostium as accused factor for affecting RF ablation time, 
and it can be interpreted as it is more feasible to ablate 
one ostium, also missing the carina, which is one of the 
difficult sites of LA ablation, saves some time.
Actually, most of the studies discussing the 
effect of LA anatomy and, especially abnormal PVs, 
were concerning AF ablation outcome and not focusing 
on procedure data.
In a study published in 2017 by Stabile 
et al., [33] and was done on 75 patients (mean age 
58±11 years, 67% male) for symptomatic PAF ablation.
The mean LA volume was 75 ± 40 ml. A normal 
anatomy (4 PVs) was documented in 40 (53 %) patients 
and abnormal anatomy (common ostium or accessory 
PVs) in 35 patients. Mean procedural and fluoroscopy 
times were 94 ± 55 and 8 ± 5 min, respectively, without 
significant differences among patients with normal or 
abnormal anatomy (92 ± 45 vs. 95 ± 64 min, p = 0.85 
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and 6 ± 3 vs. 8 ± 4 min, p = 0.65, respectively). The 
mean ablation time was 14 ± 3 min. Their conclusion 
was, there was no effect regarding LA volume and PV 
anatomy on procedural data and outcome.
Post-ablation complications
Pericardial tamponade
In our study, we had two patients (6%) 
complicated with pericardial tamponade, one in each 
group, (p > 0.05). Two patients were females, and both 
had stem pop during ablation.
Our percentage is higher than normal 
incidence, according to a recent paper by Deshmukh 
et al. [34] reported between 2000 and 2010, the overall 
incidence of a “pericardial complication” was 1.5%. The 
incidence of pericardial complications increased from 
0.74% in 2000 to 2.24% in 2010.
This study was on nationwide sample involving 
93,801 procedures and cannot be compared statistically 
with our limited number study. Nevertheless, in 
prospective European surveys on AF ablation [35], the 
incidence of tamponade was high as 6%.
One of the risk factors that increasing the 
incidence of cardiac tamponade is female sex. Women 
were 1.83-fold more likely to develop tamponade 
compared with men [8].
Steam pop developed in a result of RF 
overheating mainly. Excessive power, temperature, and 
contact force may be contributory factors.
In our study, we had 5 patients in whom (steam 
pop) were recorded, but only one had pericardial effusion.
Cappato et al. [36] reported a large series 
with cardiac tamponade during 15 of 632 AF ablation 
procedures (2.4%). Two of these patients required 
surgical intervention, and no “pop” was reported.
Pericarditis
The patient who had tamponade in 
circumferential group developed pericarditis 1 week 
post-ablation.
Pericarditis is a self-limited manifestation 
post-AF ablation and considered as a standards clinical 
course; it percentage 0% up to 50%, [8].
According to 2017 HRS/EHRA/ECAS/APHRS/
SOLAECE expert consensus statement on catheter 
and surgical ablation of AF [8], it should be considered 
a major complication following ablation if it results in 
an effusion with hemodynamic compromise or requires 
pericardiocentesis, or prolongs hospitalization more 
than 48 h, requires hospitalization, or persists for more 
than 30 days following the ablation procedure, which is 
not the case in our study.
Post-AF ablation atrial tachyarrhythmia
In our study, although we had 3 patients 
with post-ablation tachyarrhythmia belonging to the 
circumferential group, in whom there were no additional 
ablation lines, our statistics showed no significant 
difference between 2 groups (p > 0.05)
In fact, it is known that circumferential ablation 
is often complicated with atrial tachyarrhythmia, mainly 
due to adding of linear ablation such as roof, mitral 
isthmus, or anterior line; nevertheless, in other studies 
circumferential ablation with or without linear ablation 
has been associated with development of the left atrial 
tachyarrhythmia [37], [38], [39], which is rarely seen 
after segmental ablation alone [40].
Nilsson et al. [24] performed ablation in 
180 patients with persistent AF. Patients were divided into 
two groups: (Group A) those who did not require additional 
linear ablation to terminate AF (85 patients) and (Group B) 
those who did (69 patients). After 28 months follow-up, 
the incidence of left atrial tachyarrhythmias necessitating 
repeat or additional linear ablation was higher in Group A 
(76%) compared to Group B (33%) (p = 0.002).
In a randomized, prospective study by Sawhney 
et al. [31], all patients were under follow-up every 
6 months with continuous ECG monitoring for 14 days, 
atypical atrial flutters were more in circumferential with 
linear ablation group than segmental group (p = 0.002).
In a meta-analysis published by Proietti 
et al. [25], they analyzed seven studies [23], [24], [26], 
[27], [30], [31], [32]s that assessed atrial tachycardia 
recurrence as a separate outcome. A trend toward a 
higher incidence of LA tachycardia occurrence in the 
WACA group was detected, which did not reach statistical 
significance (OR, 1.53; 95% CI, 0.88–2.69; p = 0.13) 
although AF recurrence was lower.
Blanking period AF recurrence as a 
predicting factor for long-term outcome
Only predicting factor in our study for AF 
recurrence post-ablation was the early recurrence in 
the blanking period, which is defined as first 3 months 
post-catheter ablation (p < 0.05).
Recurrence within 3 months following 
catheter ablation is relatively common predictor of late 
recurrence, although different definitions of the item of 
early recurrence [41], [42], [43], [44], [45], [46], [47], 
[48], [49], [50].
Arya et al. [45] defined early recurrence as a 
sustained episode of AF within 7 days immediately after 
the procedure, while others defined it by a sustained 
episode of AF within 2 weeks [41], 1 month, [42], [43] 
6 weeks, [44], [50], and 3 months [46], [47], [48], [49] 
during the blanking period.
A recent study in 2017 by Xue et al. [51] included 
prospectively 378 patients for paroxysmal or persistent 
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AF initial ablation. After a mean follow-up of 14.71 ± 
8.58 months, 81 (65.90%) patients with early recurrence 
(defined as first 7 days post-ablation) experienced late 
recurrence and were associated with the lower event of 
free survival from late recurrence (p < 0.001).
Worth mentioning, in the same study [51], they 
concluded that left atrial size (enlargement), elderly, 
and male sex were independent factors for recurrence, 
in contrast to our study.
The use of 3-months blanking period has been 
proposed on the assumption that early recurrence will 
lead to a delayed cure and should not prompt immediate 
re-ablation attempts [52], [53], [54].
Mechanisms of arrhythmia recurrence 
within 3 months of post-ablation remain to be fully 
elucidated and may include reconnection of the 
PVs [55], inflammatory response to thermal injury and/
or pericarditis, imbalance of the autonomic nervous 
system [56], and a delayed effect of AF ablation [57].
Limitation
Nevertheless, in our prospective randomized 
study, we were very strict about inclusion and exclusion 
criteria, good selection of homogeneous patient criteria 
in both groups, and eradication of all potential biases 
that can affect our results, but our study is still limited 
due to:
1. Limited number due to inclusion criteria 
contained Pakistan air force, and long-time of 
follow-up (at least 12 months)
2. Different operators, which can be considered 
as a heterogeneity due to a small sample
3. Different mapping systems, and ablation catheters 
with different characteristics (e.g., contact force)
4. Deficiency of long monitoring devices 
(e.g., intracardiac loop recorder), and we 
depended mainly on ECG Holter 48–72 h as a 
routine for asymptomatic cases, and documented 
ECG or Holter for symptomatic cases
5. Pulmonary venography was not listed as a 
routine imaging tool post-ablation to exclude 
PV stenosis because we depended primary on 
clinical manifestation (unexplained cough and 
dyspnea).
In any way according to last American AF 
guidelines 2017 [8], even there is a PV stenosis but 
asymptomatic and does not need intervention (surgically 
or stenting) not considered as a complication.
Conclusions
Atrial fibrillation is an independent risk factor 
causing mortality and its management is still missing 
full cure, although rapidly evoked advanced technology, 
last years.
However, many theories for the best method 
of AF ablation, PVI remained the cornerstone and an 
indispensable step in any method.
There is no definitive, prospective, randomized 
study published to date, with a large enough population 
of patients, over an acceptable duration of follow-up, 
and with adequate monitoring to ensure identification 
of AF recurrence comparing segmental versus 
circumferential ablation method.
In our study, we had tried to get away from all 
biases that were found in publications to have clear 
definitive results regarding both methods.
In the circumferential ablation group, we were 
very strict about no adding of any linear ablations, which 
are unfair and intolerable factor affecting long-term 
outcomes and causing post-ablation tachyarrhythmia.
Furthermore, in the segmental group, we 
tried – what we called – extra ostial ablation not to be 
complicated with PV stenosis.
No surprise, there are some centers still 
adopting segmental ablation as standard method for 
PAF ablation even primary or redo, as some centers 
in France and in Japan where segmental ablation is 
modified to be for anterior wall with linear RF on the 
posterior wall.
Nevertheless, the similarity of our results 
to a published abstract in last APHRS 2018 with 
retrospective long-term (10 years) follow-up study of 
comparison between segmental and circumferential 
PV isolation, we are waiting for the results of the 
clinical trial of effectiveness study of circumferential 
versus segmental ablation in PAF that is recorded by 
ClinicalTrials.gov Identifier: NCT02106663.
It is started by Gregory Kent Feld, University of 
California, San Diego, in July 2012 and expected to be 
released in May 2020.
Recommendations
• We can use extra-ostial segmental ablation 
of PVs safely specifically in cases where 
circumferential ablation is not feasible due 
to the unavailability of 3D electro-anatomical 
mapping or in redo cases in which reconnection 
points of PVs are the target
• Segmental ablation is as effective as 
circumferential ablation and decreases the 
incidence of evolving post-AF ablation atrial 
flutter
• In segmental ablation, we should avoid ostial 
ablation by detection of PV ostium precisely.
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